Cite
HARVARD Citation
Taxonera, C. et al. (2017). Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Inflammatory bowel diseases. 23 (8), pp. 1394-1402. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Taxonera, C. et al. (2017). Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. Inflammatory bowel diseases. 23 (8), pp. 1394-1402. [Online].